Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn

por Miller, Michael, Bhatt, Deepak L, Brinton, Eliot A, Jacobson, Terry A, Steg, Philippe Gabriel, Pineda, Armando Lira, Ketchum, Steven B, Doyle, Ralph T, Tardif, Jean-Claude, Ballantyne, Christie M
Publicado 2023

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

por Bhatt, Deepak L., Steg, Ph. Gabriel, Brinton, Eliot A., Jacobson, Terry A., Miller, Michael, Tardif, Jean‐Claude, Ketchum, Steven B., Doyle, Ralph T., Murphy, Sabina A., Soni, Paresh N., Braeckman, Rene A., Juliano, Rebecca A., Ballantyne, Christie M.
Publicado 2017

Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT

por Olshansky, Brian, Bhatt, Deepak L., Miller, Michael, Steg, Ph. Gabriel, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Doyle, Ralph T., Juliano, Rebecca A., Jiao, Lixia, Kowey, Peter R., Reiffel, James A., Tardif, Jean‐Claude, Ballantyne, Christie M., Chung, Mina K.
Publicado 2023

REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results

por Olshansky, Brian, Bhatt, Deepak L, Miller, Michael, Steg, Ph. Gabriel, Brinton, Eliot A, Jacobson, Terry A, Ketchum, Steven B, Doyle Jr, Ralph T, Juliano, Rebecca A, Jiao, Lixia, Granowitz, Craig, Tardif, Jean-Claude, Mehta, Cyrus, Mukherjee, Rajat, Ballantyne, Christie M, Chung, Mina K
Publicado 2020

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL

por Majithia, Arjun, Bhatt, Deepak L., Friedman, Allon N., Miller, Michael, Steg, Ph. Gabriel, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Juliano, Rebecca A., Jiao, Lixia, Doyle, Ralph T., Granowitz, Craig, Budoff, Matthew, Preston Mason, R., Tardif, Jean-Claude, Boden, William E., Ballantyne, Christie M.
Publicado 2021

REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States

por Bhatt, Deepak L., Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Steg, Ph. Gabriel, Ketchum, Steven B., Doyle, Ralph T., Juliano, Rebecca A., Jiao, Lixia, Granowitz, Craig, Tardif, Jean-Claude, Olshansky, Brian, Chung, Mina K., Gibson, C. Michael, Giugliano, Robert P., Budoff, Matthew J., Ballantyne, Christie M.
Publicado 2020

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses

por Peterson, Benjamin E., Bhatt, Deepak L., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Juliano, Rebecca A., Jiao, Lixia, Doyle, Ralph T., Granowitz, Craig, Gibson, C. Michael, Pinto, Duane, Giugliano, Robert P., Budoff, Matthew J., Tardif, Jean-Claude, Verma, Subodh, Ballantyne, Christie M.
Publicado 2020

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI

por Peterson, Benjamin E., Bhatt, Deepak L., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Juliano, Rebecca A., Jiao, Lixia, Doyle, Ralph T., Granowitz, Craig, Gibson, C. Michael, Pinto, Duane, Giugliano, Robert P., Budoff, Matthew J., Tardif, Jean‐Claude, Verma, Subodh, Ballantyne, Christie M.
Publicado 2022